To Investigate the Safety and Tolerability of TC-5214 Following Oral Administration of Multiple Doses for up to 8 Days

NCT01145768 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: TC-5214
DRUG: TC-5214
DRUG: Placebo

Sponsor

AstraZeneca